Innate Pharma

Developer of therapeutic human monoclonal antibodies designed to offer treatment of cancer and infectious diseases. The company's human monoclonal antibodies and antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of promising antibodies from humans or animals, enabling healthcare organizations to provide patients with quality care in a cost-efficient manner.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Developer a Natural killer (NK) cell therapy platform designed for targeting hematological malignancies and solid tumors. The company's technology is based on a dual-targeted Natural killer (NK) cell expressing both a chimeric antigen receptor (CAR) targeting a known tumor antigen and a Tumor necrosis factor (TNF), related apoptosis-inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5), enabling pharmaceutical companies to enhance its efficacy in killing tumor cells.